Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION
Rebecca B. Price, Dan V. Iosifescu, James W. Murrough, et al.
Depression and Anxiety (2014) Vol. 31, Iss. 4, pp. 335-343
Open Access | Times Cited: 317

Showing 26-50 of 317 citing articles:

<p>Ketamine and depression: a narrative review</p>
Alexandrine Corriger, Gisèle Pickering
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 3051-3067
Open Access | Times Cited: 184
Clinical applications of hallucinogens: A review.
Albert Garcia‐Romeu, Brennan Kersgaard, Peter H. Addy
Experimental and Clinical Psychopharmacology (2016) Vol. 24, Iss. 4, pp. 229-268
Open Access | Times Cited: 175
An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation
Lena Brundin, Carl M. Sellgren, Chai K. Lim, et al.
Translational Psychiatry (2016) Vol. 6, Iss. 8, pp. e865-e865
Open Access | Times Cited: 169
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers
Dmitriy Matveychuk, Rejish K. Thomas, Jennifer Swainson, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 164
Ketamine treatment for depression: a review
Mani Yavi, Holim Lee, Ioline D. Henter, et al.
Discover Mental Health (2022) Vol. 2, Iss. 1
Open Access | Times Cited: 85
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
Domenico De Berardis, Michele Fornaro, Alessandro Valchera, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 2888-2888
Open Access | Times Cited: 159
Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
Wei Zheng, Yanling Zhou, Weijian Liu, et al.
Journal of Psychiatric Research (2018) Vol. 106, pp. 61-68
Closed Access | Times Cited: 156
Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
Gerard Sanacora, Alan F. Schatzberg
Neuropsychopharmacology (2014) Vol. 40, Iss. 2, pp. 259-267
Open Access | Times Cited: 154
Convergent Mechanisms Underlying Rapid Antidepressant Action
Panos Zanos, Scott M. Thompson, Ronald S. Duman, et al.
CNS Drugs (2018) Vol. 32, Iss. 3, pp. 197-227
Open Access | Times Cited: 154
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
Dawn F. Ionescu, Kate H. Bentley, Matthias Eikermann, et al.
Journal of Affective Disorders (2018) Vol. 243, pp. 516-524
Closed Access | Times Cited: 149
Ketamine and other glutamate receptor modulators for depression in adults
Caroline Caddy, Ben H. Amit, Tayla McCloud, et al.
Cochrane library (2015)
Closed Access | Times Cited: 146
Neuroinflammation in suicide: Toward a comprehensive model
Philippe Courtet, Lucas Giner, Maude Sénèque, et al.
The World Journal of Biological Psychiatry (2015) Vol. 17, Iss. 8, pp. 564-586
Closed Access | Times Cited: 131
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Marc S. Lener, Bashkim Kadriu, Carlos A. Zarate
Drugs (2017) Vol. 77, Iss. 4, pp. 381-401
Open Access | Times Cited: 123
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Todd D. Gould, Carlos A. Zarate, Scott M. Thompson
The Annual Review of Pharmacology and Toxicology (2018) Vol. 59, Iss. 1, pp. 213-236
Open Access | Times Cited: 117
Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model
Youge Qu, Chun Yang, Qian Ren, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 114
Ketamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Lael Reinstatler, Nagy A. Youssef
Drugs in R&D (2015) Vol. 15, Iss. 1, pp. 37-43
Open Access | Times Cited: 113
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression
Jennifer L. Phillips, Sandhaya Norris, Jeanne Talbot, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 4, pp. 606-612
Open Access | Times Cited: 111
Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences
Hubertus Himmerich, Carol Kan, Katie Au, et al.
Pharmacology & Therapeutics (2020) Vol. 217, pp. 107667-107667
Closed Access | Times Cited: 101
Classics in Chemical Neuroscience: Ketamine
Marshall Tyler, Harmony B. Yourish, Dawn F. Ionescu, et al.
ACS Chemical Neuroscience (2017) Vol. 8, Iss. 6, pp. 1122-1134
Closed Access | Times Cited: 96
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis
Jiaqi Xiong, Orly Lipsitz, David Chen‐Li, et al.
Journal of Psychiatric Research (2020) Vol. 134, pp. 57-68
Closed Access | Times Cited: 95
Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer
Stephen Ross, Gabrielle Agin-Liebes, Sharon L. Lo, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 553-562
Open Access | Times Cited: 95
A Circadian Genomic Signature Common to Ketamine and Sleep Deprivation in the Anterior Cingulate Cortex
Ricardo Orozco-Solís, Emilie Montellier, Lorena Aguilar‐Arnal, et al.
Biological Psychiatry (2017) Vol. 82, Iss. 5, pp. 351-360
Open Access | Times Cited: 94
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder
Brittany A. Jaso, Mark J. Niciu, Nicolas D. Iadarola, et al.
Current Neuropharmacology (2016) Vol. 15, Iss. 1, pp. 57-70
Open Access | Times Cited: 90
Glutamatergic Modulators in Depression
Ioline D. Henter, Rafael T. de Sousa, Carlos A. Zarate
Harvard Review of Psychiatry (2018) Vol. 26, Iss. 6, pp. 307-319
Open Access | Times Cited: 86
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation
Richard J. Zeifman, Anne Catherine Wagner, Ros Watts, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 86

Scroll to top